Skip to main content

Table 2 ETS, DpR and outcomes according to the primary tumor location in three RCTs

From: Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Characteristic PRIME FIRE-3 PEAK
Left-sided Right-sided Left-sided Right-sided Left-sided Right-sided
Pani + FOLFOX4
(n = 169)
FOLFOX
(n = 159)
Pani + FOLFOX4
(n = 39)
FOLFOX
(n = 49)
Cet + FOLFIRI
(n = 124)
Bev + FOLFIRI
(n = 133)
Cet + FOLFIRI
(n = 30)
Bev + FOLFIRI
(n = 38)
Pani+mFOLFOX6
(n = 53)
Bev + mFOLFOX6
(n = 54)
Pani+mFOLFOX6
(n = 22)
Bev + mFOLFOX6
(n = 14)
ETS,n (%) 104 (62) 57 (36) 12 (31) 15 (31) 88 (71) 67 (50.4) 17 (56.7) 16 (42.1) 31 (58) 22 (41) 12 (55) 3 (21)
Median PFS (95% CI), months 14.8 (12.5–18.5) 11.1 (9.3–13.9) 14.9 (7.4–27.2) 7.3 (5.6–11.1) NR NR 7.8 (2.1–20.5) 13.4 (3.8–21.2) 16.2 (13.0–20.3) 12.9 (9.3–18.6) 10.8 (5.5–15.8) 18.4 (16.6–21.4)
HR (95%CI) 1.718 (0.832, 3.545) P = 0.137
Median OS (95% CI), months 35.0 (29.8–41.9) 31.7 (23.8–38.1) 27.2 (8.0–57.4) 23.6 (7.2–34.5) NR NR 27.9 (18.3–37.1) 23.2 (21.0–43.7) 55.4 (41.3–63.0) 48.5 (28.9-NE) 24.6 (10.3–48.4) 26.2 (21.0–31.3)
HR (95%CI) 1.054 (0.453, 2.453) P = 0.903
No. of ETS,n (%) 49 (29) 87 (55) 22 (56) 27 (55) 36 (29) 66 (49.6) 13 (43.3) 22 (57.9) 20 (38) 28 (52) 7 (32) 9 (64)
Median PFS (95% CI), months 9.4 (5.8–13.8) 6.9 (5.5–7.8) 6.5 (4.0–9.9) 6.9 (3.6–11.9) NR NR 2.8 (1.8–5.8) 5.2 (3.1–8.6) 11.6 (7.5–16.4) 12.4 (7.4–13.0) 5.8 (3.6–9.8) 12.6 (1.8–13.8)
HR (95%CI)1.743 (0.841,3.609) P = 0.129
Median OS (95% CI), months 19.9 (13.5–27.5) 17.2 (14.2–20.7) 10.6 (6.1–22.5) 13.1 (6.1–18.8) NR NR 11.7 (5.9–18.9) 15.9 (13.0–24.0) 34.2 (17.3–48.0) 27.7 (21.0–32.0) 15.3 (5.8–46.1) 23.3 (6.0–29.0)
HR (95%CI) 1.902 (0.892, 4.056) P = 0.0902
Median DpR % 59 49 37 50 42 30.8 25.8 17.7 70 48 50 45
Any resection, n (%) 25 (15) 21 (13) 4 (10) 6 (12) NR NR NR NR 9 (17) 10 (19) 2 (9) 1 (7)
R0 resection, n (%) 19 (11) 16 (10) 2 (5) 1 (2) NR NR NR NR 7 (13) 6 (11) 1 (5) 1 (7)
  1. ETS status was unknown for some patients only FIRE-3 reported the HR for PFS and OS
  2. NR not reported, NE not evaluable, cet cetuximab, pani panitumumab, bev bevacizumab